The Coca-Cola Company (KO), Tesla Motors Inc (TSLA) Among Stocks to Sell Near 52-Week Highs

A blast to the past
It’s occasionally very difficult to value biotech stocks, because of the wide range of outcomes possible given their pipelines. Other times, as in the case with Regulus Therapeutics Inc (NASDAQ:RGLS), I bang my head against a table and wonder what the heck investors are thinking.

Regulus Therapeutics Inc (NASDAQ:RGLS), which was formed by Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) in 2007, is a microRNA therapeutics company that has access to approximately 900 oligonucleotide technologies that it can use in its microRNA research. Outside of these patents, Regulus is a ship adrift at sea.

Regulus’ entire pipeline as of now is completely pre-clinical, and it likely isn’t going to submit an IND to the Food and Drug Administration until next year at the earliest. In addition, one of Regulus’ lead drug candidates, which it’s collaborating on with GlaxoSmithKline plc (ADR) (NYSE:GSK), is an intravenous hepatitis-C vaccine known as miR-122. As Foolish community member zzlangerhans so poignantly put it, “Where has management been for the last five years?” Gilead Sciences, Inc. and AbbVie Inc (NYSE:ABBV)‘s hep-C oral pills are the wave of the future and Regulus is years upon years away from having a viable drug opportunity.

Foolish roundup
This week, it’s all about what can you do for me now. Both Regulus and ECOtality have rallied because of their potential, but the actual bottom-line results likely won’t be there until the latter half of this decade at the earliest. With regard to Cedar Fair, it’s all about the potential for inconsistencies and the multiple factors of its business that it can’t control that makes me want to click the “avoid” button.

I’m so confident in my three calls that I plan to make a CAPScall of underperform on each one. The question is: Would you do the same?

The article 3 Stocks Near 52-Week Highs Worth Selling originally appeared on Fool.com.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool recommends Coca-Cola, Gilead Sciences, and Tesla Motors. The Motley Fool owns shares of Tesla Motors.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.